Compounds > dm 232
Page last updated: 2024-12-11

dm 232

Description

DM 232: a cognition-enhancing agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9861054
CHEMBL ID140717
SCHEMBL ID22032048
MeSH IDM0364876

Synonyms (26)

Synonym
CHEMBL140717
unifiram
pyrrolo[1,2-a]pyrazin-6(2h)-one, 2-[(4-fluorophenyl)sulfonyl]hexahydro-
272786-64-8
AKOS017975218
dm-232
DTXSID00432024
2-((4-fluorophenyl)sulfonyl)hexahydropyrrolo(1,2-a)pyrazin-6(2h)-one
dm 232
unii-n4024ln29g
N4024LN29G ,
pyrrolo(1,2-a)pyrazin-6(2h)-one, 2-((4-fluorophenyl)sulfonyl)hexahydro-
AC-31952
C90620
2-((4-fluorophenyl)sulfonyl)hexahydropyrrolo[1,2-a]pyrazin-6(2h)-one
BS-16342
2-(4-fluorophenyl)sulfonyl-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-6-one
Q6590512
AMY19531
2-[(4-fluorophenyl)sulfonyl]hexahydropyrrolo[1,2-a]pyrazin-6(2h)-one
mfcd20526948
dm232
A934246
SCHEMBL22032048
CS-0103168
HY-125931
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID131296Effect of 0.1 mg/kg compound, when administered intraperitoneally, on Amnesia induced by Baclofen (2 mg/Kg ip) in mouse passive Avoidance test on 1st day2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
AID388502Effect on passive avoidance in mouse treated 20 mins before training session2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators.
AID1194502Cognition enhancing activity in sc dosed mouse assessed as reversal of scopolamine-induced amnesia measured up to 24 hrs treated 20 mins before training session by passive-avoidance test2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
Substituted piperazines as nootropic agents: 2- or 3-phenyl derivatives structurally related to the cognition-enhancer DM235.
AID388512Antiamnesic activity in scopolamine-induced mouse assessed as latency time to enter dark room in retention session at 0.001 mg/kg, ip treated 20 mins before training session by passive avoidance test2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators.
AID127580Change in entry latency expressed as [(entry latency on day 2)-(entry latency on day 1)]2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
AID388515Antiamnesic activity in ip dosed mouse assessed as reversal of scopolamine-induced memory loss treated 20 mins before training session by passive avoidance test2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators.
AID388521Toxicity in mouse assessed as spontaneous motility and inspection activity after 5 mins by hole board test2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators.
AID388520Toxicity in mouse assessed as motor coordination after 45 mins by rotarod test2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators.
AID131293Effect of 0.1 mg/kg compound, when administered intraperitoneally along with saline, on Amnesia in mouse passive Avoidance test on 1st day2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
AID388513Antiamnesic activity in scopolamine-induced mouse assessed as latency time to enter dark room in training session at 0.001 mg/kg, ip treated 20 mins before training session by passive avoidance test2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators.
AID131294Effect of 0.1 mg/kg compound, when administered intraperitoneally along with saline, on Amnesia in mouse passive Avoidance test on 2nd day2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
AID131426Effect of 0.1 mg/kg compound, when administered intraperitoneally, on Amnesia induced by Baclofen (2 mg/Kg ip) in mouse passive Avoidance test on 2nd day2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
AID131429Effect of 0.1 mg/kg compound, when administered intraperitoneally, on Amnesia induced by diphenhydramine (20 mg/Kg) in mouse passive Avoidance test on 1st day2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
AID131295Effect of 0.1 mg/kg compound, when administered intraperitoneally, on Amnesia induced Clonidine (0.125 mg/kg) in mouse passive Avoidance test on 1st day2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
AID388503Effect on passive avoidance in mouse assessed as latency time to enter dark room in training session at 0.01 mg/kg, ip treated 20 mins before training session2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators.
AID1427530Cognition enhancing effect in ip dosed mouse assessed as reversal of scopolamine-induced amnesia treated 20 mins prior to training session followed by scopolamine challenge immediately after training session by passive avoidance test2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Piperazines as nootropic agents: New derivatives of the potent cognition-enhancer DM235 carrying hydrophilic substituents.
AID388501Effect on passive avoidance in mouse assessed as latency time to enter dark room in retention session at 0.01 mg/kg, ip treated 20 mins before training session2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators.
AID131428Effect of 0.1 mg/kg compound, when administered intraperitoneally, on Amnesia induced by diphenhydramine (20 mg/Kg) in mouse passive Avoidance test on 2 nd day2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
AID127581Change in entry latency expressed as [(latency on day 2)-(latency on day 1)]2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
AID131427Effect of 0.1 mg/kg compound, when administered intraperitoneally, on Amnesia induced by Clonidine (0.125 mg/Kg ip) in mouse passive Avoidance test on 2 nd day2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (70.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.88 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
baclofen
[no description available]		210amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		210clonidine;
imidazoline
kynurenic acid
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.		2.0110monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
mecamylamine
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.		210primary aliphatic amine
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		2.9740organonitrogen compound;
organooxygen compound
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		2.0110mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		5.1580pyrrole;
secondary amine
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		2.0110amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		2103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline: structure given in first source; neuroprotectant for cerebral ischemia; AMPA receptor antagonist		2.0110naphthalenes;
sulfonic acid derivative
dm 235
DM 235: structure in first source		10.1680
enalapril
Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).		2.1510dicarboxylic acid monoester;
dipeptide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug
sapunifiram
sapunifiram: structure in first source		2.4820
scopolamine hydrobromide
[no description available]		2.4120
ConditionIndicatedRelationship StrengthStudiesTrials
Amnesia-Memory Loss
[description not available]		02.7230
Amnesia
Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)		02.7230
chemdatabank.com